PROM1 and neoplasm: Finally, we validated that VNP-siALKBH5 plus Oxaliplatin also markedly reduced tumor growth (Fig. 8N) along with down-regulation of β-catenin, LGR5 and CD133 (Fig. 8O and Fig. S13G) and induction of cell apoptosis (Fig. 8O and Fig. S13H) in CSC28, indicating in vivo siALKBH5 enhances chemotherapy efficacy in CRC.